Journal
CURRENT CANCER DRUG TARGETS
Volume 18, Issue 3, Pages 222-230Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009617666170427103732
Keywords
STEAP1; Cancer; DNA vaccines; Monoclonal antibodies; Small noncoding RNA; prostate cancer
Categories
Funding
- FEDER through the POCI - COMPETE - Operational Programme Competitiveness and Internationalization in Axis I - Strengthening research, technological development and innovation [007491]
- FCT - Foundation for Science and Technology [UID/Multi/00709]
Ask authors/readers for more resources
Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available